TWI743019B - 治療及預防異體抗體所驅動之慢性移植體對抗宿主疾病之方法 - Google Patents

治療及預防異體抗體所驅動之慢性移植體對抗宿主疾病之方法 Download PDF

Info

Publication number
TWI743019B
TWI743019B TW103141826A TW103141826A TWI743019B TW I743019 B TWI743019 B TW I743019B TW 103141826 A TW103141826 A TW 103141826A TW 103141826 A TW103141826 A TW 103141826A TW I743019 B TWI743019 B TW I743019B
Authority
TW
Taiwan
Prior art keywords
cgvhd
substituted
unsubstituted
allogeneic
inhibitor
Prior art date
Application number
TW103141826A
Other languages
English (en)
Chinese (zh)
Other versions
TW201605454A (zh
Inventor
布魯斯Ｒ 布雷札
萊恩 富林
Original Assignee
美商製藥公司
美國明尼蘇達大學評議委員會
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商製藥公司, 美國明尼蘇達大學評議委員會 filed Critical 美商製藥公司
Publication of TW201605454A publication Critical patent/TW201605454A/zh
Application granted granted Critical
Publication of TWI743019B publication Critical patent/TWI743019B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
TW103141826A 2013-12-02 2014-12-02 治療及預防異體抗體所驅動之慢性移植體對抗宿主疾病之方法 TWI743019B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361910944P 2013-12-02 2013-12-02
US61/910,944 2013-12-02
US201461973178P 2014-03-31 2014-03-31
US61/973,178 2014-03-31

Publications (2)

Publication Number Publication Date
TW201605454A TW201605454A (zh) 2016-02-16
TWI743019B true TWI743019B (zh) 2021-10-21

Family

ID=53270044

Family Applications (3)

Application Number Title Priority Date Filing Date
TW103141826A TWI743019B (zh) 2013-12-02 2014-12-02 治療及預防異體抗體所驅動之慢性移植體對抗宿主疾病之方法
TW112113060A TW202402295A (zh) 2013-12-02 2014-12-02 治療及預防異體抗體所驅動之慢性移植體對抗宿主疾病之方法
TW110135203A TW202228700A (zh) 2013-12-02 2014-12-02 治療及預防異體抗體所驅動之慢性移植體對抗宿主疾病之方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW112113060A TW202402295A (zh) 2013-12-02 2014-12-02 治療及預防異體抗體所驅動之慢性移植體對抗宿主疾病之方法
TW110135203A TW202228700A (zh) 2013-12-02 2014-12-02 治療及預防異體抗體所驅動之慢性移植體對抗宿主疾病之方法

Country Status (14)

Country Link
US (6) US20150157634A1 (OSRAM)
EP (1) EP3076975A4 (OSRAM)
JP (5) JP2017501140A (OSRAM)
KR (2) KR20230104754A9 (OSRAM)
CN (2) CN105939717B (OSRAM)
AU (4) AU2014360758B2 (OSRAM)
BR (1) BR112016012158A2 (OSRAM)
CA (2) CA2932255C (OSRAM)
EA (1) EA201691020A1 (OSRAM)
IL (4) IL315228A (OSRAM)
MX (2) MX389020B (OSRAM)
PH (2) PH12020552048A1 (OSRAM)
TW (3) TWI743019B (OSRAM)
WO (1) WO2015084857A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9296753B2 (en) 2012-06-04 2016-03-29 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
AU2014339815B2 (en) 2013-10-25 2020-03-26 Pharmacyclics Llc Methods of treating and preventing graft versus host disease
AR102871A1 (es) 2014-12-03 2017-03-29 Pharmacyclics Llc Métodos de tratamiento de fibrosis
EP3432879B1 (en) * 2016-03-22 2021-01-06 Mayo Foundation for Medical Education and Research Using fatty acid synthase inhibitors to treat fibrosis
WO2018002958A1 (en) * 2016-06-30 2018-01-04 Sun Pharma Advanced Research Company Limited Novel hydrazide containing compounds as btk inhibitors
US20200054721A1 (en) * 2016-10-21 2020-02-20 Bruce R. Blazar Materials and methods for treating or preventing graft-versus-host-disease
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
WO2021038540A1 (en) 2019-08-31 2021-03-04 Sun Pharma Advanced Research Company Limited Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
US12496303B2 (en) 2020-10-19 2025-12-16 Washington University Conditioning agents for use in allogeneic hematopoietic stem cell transplantation
US20240025990A1 (en) * 2020-12-01 2024-01-25 City Of Hope Prevention and treatment of graft-versus-host disease (gvhd)
EP4284434A4 (en) * 2021-01-30 2024-12-25 BeiGene Switzerland GmbH METHODS FOR TREATING CHRONIC ACTIVE ANTIBODY-MEDIATED REJECTION USING BTK INHIBITORS
US20240287781A1 (en) 2023-02-28 2024-08-29 Toto Ltd. Wall-mounted flush toilet

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI620565B (zh) * 2013-10-25 2018-04-11 製藥公司 治療及預防移植物抗宿主病之方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
US20060182723A1 (en) * 2005-01-25 2006-08-17 Spellberg Brad J Methods for treating refractory infections in neutropenic individuals
RU2008133161A (ru) * 2006-01-13 2010-02-20 Фармасайкликс, Инк. (Us) Ингибиторы тирозин киназ и их применение
EP2529621B1 (en) * 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
EP3311818A3 (en) * 2008-07-16 2018-07-18 Pharmacyclics, LLC Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
JP5656976B2 (ja) * 2009-04-29 2015-01-21 ローカス ファーマシューティカルズ インコーポレイテッド ピロロトリアジン化合物
CA2772204A1 (en) * 2009-08-31 2011-03-03 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
US20120071497A1 (en) * 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
EA031737B1 (ru) * 2010-06-03 2019-02-28 Фармасайкликс, Инк. Применение ингибиторов тирозинкиназы брутона (btk) для лечения лейкоза и лимфомы
BR112014000314A2 (pt) * 2011-07-08 2017-01-10 Novartis Ag derivados de pirrolo pirimidina
EP2836214B1 (en) * 2012-04-11 2018-06-27 Acerta Pharma B.V. Bruton's tyrosine kinase inhibitors for hematopoietic mobilization
DK2854850T3 (da) * 2012-05-25 2021-08-30 Sloan Kettering Inst Cancer Res Sammensætninger til behandling eller forebyggelse af strålingssygdom og gi-syndrom
WO2014127200A1 (en) * 2013-02-15 2014-08-21 Immunomedics, Inc. Chimeric and humanized anti-histone antibodies
IL315294A (en) * 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI620565B (zh) * 2013-10-25 2018-04-11 製藥公司 治療及預防移植物抗宿主病之方法

Also Published As

Publication number Publication date
AU2020204276A1 (en) 2020-07-16
IL315228A (en) 2024-10-01
IL276683A (en) 2020-09-30
TW201605454A (zh) 2016-02-16
TW202228700A (zh) 2022-08-01
AU2014360758B2 (en) 2020-03-26
CN105939717A (zh) 2016-09-14
KR20230104754A (ko) 2023-07-10
JP2024072291A (ja) 2024-05-27
PH12020552048A1 (en) 2022-05-11
EP3076975A1 (en) 2016-10-12
CN105939717B (zh) 2019-09-13
PH12016501051A1 (en) 2016-08-15
CN110478353A (zh) 2019-11-22
WO2015084857A1 (en) 2015-06-11
IL292522A (en) 2022-06-01
JP2023029899A (ja) 2023-03-07
US20210177854A1 (en) 2021-06-17
CA3210338A1 (en) 2015-06-11
JP2017501140A (ja) 2017-01-12
KR20230104754A9 (ko) 2024-11-15
US20240293409A1 (en) 2024-09-05
EA201691020A1 (ru) 2017-01-30
EP3076975A4 (en) 2017-05-03
TW202402295A (zh) 2024-01-16
AU2022203810B2 (en) 2024-10-03
KR20160085817A (ko) 2016-07-18
US20150157634A1 (en) 2015-06-11
CA2932255A1 (en) 2015-06-11
US20230100137A1 (en) 2023-03-30
CA2932255C (en) 2023-10-10
CN110478353B (zh) 2022-12-30
AU2022203810A1 (en) 2022-06-23
US20250381188A1 (en) 2025-12-18
JP2025118595A (ja) 2025-08-13
AU2014360758A1 (en) 2016-06-16
BR112016012158A2 (pt) 2017-09-26
AU2024278490A1 (en) 2025-01-09
MX2016006955A (es) 2016-09-07
JP2020105181A (ja) 2020-07-09
US20180078558A1 (en) 2018-03-22
IL245715A0 (en) 2016-07-31
MX389020B (es) 2025-03-20
MX2022000209A (es) 2022-02-03

Similar Documents

Publication Publication Date Title
TWI743019B (zh) 治療及預防異體抗體所驅動之慢性移植體對抗宿主疾病之方法
AU2022202686B2 (en) Methods of treating and preventing graft versus host disease
AU2022243600A1 (en) Alk-5 inhibitors and uses thereof
HK40031991B (zh) 治疗和预防移植物抗宿主病的方法
HK40086449A (en) Methods of treating and preventing graft versus host disease